



- Dermatology
beyond the skin

COLLABORATION AGREEMENT (PATIENT ORGANIZATIONS) SUPPORT

between

Atopisk Eksem Forening

and

LEO PHARMA A/S

TABLE OF CONTENTS

1	PURPOSE	3
2	NAME OF THE PROJECT	3
3	OBLIGATIONS OF THE PARTIES.....	3
4	TIME AND PLACE	5
5	FINANCIAL SUPPORT	5
6	INDIRECT- AND NON-FINANCIAL SUPPORT	5
7	TRANSPARENCY AND DISCLOSURE	5
8	USE OF THE PATIENT ORGANIZATION'S LOGO.....	5
9	INDEPENDENCE AND CONFLICT OF INTEREST	5
10	TERM AND TERMINATION	6
11	DATA PROTECTION.....	6
12	LAW AND VENUE	6
13	SIGNATURES.....	6

THIS AGREEMENT ("Agreement") is made and entered into by and between:

- (1) **LEO Pharma A/S**, a company organized and existing under the laws of Denmark and having its registered office at Industriparken 55, 2750 Ballerup, Denmark, with its company registration no. 56759514 ("**LEO Pharma**"), and
- (2) **Atopisk Eksem Forening**, an organization organized and existing under the laws of Denmark and having its registered office at Hvidovrevej 108, 1. tv., 2650 Hvidovre, Denmark ("**Patient Organization**"),

hereinafter individually referred to as "**Party**" and collectively as "**Parties**",

WHEREAS:

- (A) **LEO Pharma** is a research-based pharmaceutical company that develops, manufactures and markets pharmaceutical products to patients within dermatology and thrombosis;
- (B) **The Patient Organization** is an organization working with enabling better conditions for people with atopic eczema and
- (C) **LEO Pharma** has invited **The Patient Organization** to take part in the event hosted by **LEO Pharma**.

NOW THEREFORE, the Parties have agreed as follows:

1 PURPOSE

- 1.1 The purpose of this Agreement is to describe the terms and conditions for the collaboration between **LEO Pharma** and its Affiliates and the Patient Organization in connection with establishing a multi stakeholder-conversation about the research eco-system in Denmark and beyond. For the purpose of this Agreement "**Affiliate**" is defined as any company, corporation, firm, partnership or other entity controlling or controlled by **LEO Pharma**.

2 NAME OF THE EVENT

- 2.1 The name of the Event is "Hvordan sikrer vi dansk sundhedsforskning i verdensklasse?" ("**Event**").

3 OBLIGATIONS OF THE PARTIES

- 3.1 **LEO Pharma** undertakes during the term of the Agreement to arrange/host a Roundtable Discussion about the research ecosystem in Denmark. The event will take place on June 13th 2024 at 09.30-11.00 am at Restaurant Sommer, Havnegade 19, 3770 Allinge.
- 3.2 **The Patient Organization** undertakes during the term of this Agreement to take part in the Panel Discussion Meeting hosted by **LEO Pharma** on Thursday June 13th 2024 at 09.30-11am at Restaurant Sommer, Havnegade 19, 3770 Allinge,
- 3.3 **The Patient Organization** represents and warrants to comply with any and all applicable laws, rules, regulations, government regulatory requirements and guidelines in force from time to time in connection with the Event.
- 3.4 **The Patient Organization** acknowledges that **LEO Pharma** has committed to comply with a number of national and international industry ethical codes including but not limited to:

- the International Federation of Pharmaceutical Manufactures and Associations's (IFPMA) Code of Practice;
 - the European Federation of Pharmaceutical Industries and Associations (EFPIA) Code of Practice;
 - the Danish Ethical Committee for the Pharmaceutical Industry (ENLI) Code of Practice on Promotion etc., of Medicinal Products aimed at Healthcare Professionals;
 - the ENLI Ethical Rules for Collaboration between Patient Organizations, etc., and the Pharmaceutical Industry;
 - the ENLI Ethical Rules for Negotiations with Decision-makers (Lobbying Code);
- Patientforeningskoder/Danish Patient Association Code relating to the relationship between the pharmaceutical industry and patient organizations the country where the activity takes place.

The Patient Organization therefore undertakes to comply with these ethical codes in connection with the Event.

3.5 The Patient Organization and its representatives shall at all times conform to the Sustainability Standards for LEO Pharma Business Partners (the "Sustainability Standards"). The latest effective version of the Sustainability Standards are always available at www.leo-pharma.com/thirdparty. Upon request, The Patient Organization shall provide information on its level of compliance with the Sustainability Standards so that LEO Pharma can assess whether the Patient Organization actually complies with these or not and grant rights to LEO Pharma to conduct a compliance audit the Patient Organization. The Patient Organization shall at all times and promptly take all appropriate steps to resolve and correct any identified non-conformity.

3.6 [Any rights and results generated from the Event are owned by the Patient Organization. The Patient Organization grants LEO Pharma a worldwide, royalty-free, non-exclusive, perpetual right to use the results of the Event for any scientific, marketing and/or commercial purpose. LEO Pharma may in that connection refer to the fact that the Project has been sponsored by LEO Pharma.

3.7 LEO Pharma is subject to strict laws, regulations and ethical codes relating to communications on medicinal products, including the prohibition of the promotion of prescription only medicinal products of LEO Pharma to the general public (directly or indirectly). As LEO Pharma may be held responsible for the content of any output of the projects sponsored by LEO Pharma, the Patient Organization therefore agrees, upon request, to send a draft of any output to be published in connection with the Project for the internal review and approval by LEO Pharma. The review and approval is not intended to compromise the Patient Organization's independence, but to ensure that LEO Pharma complies with applicable laws, regulations and ethical codes.

3.8 The Patient Organization confirms that it has obtained and will maintain all consents and permissions necessary to conduct its business including the Event.

3.9 Contact persons in matters related to this Agreement:

From LEO Pharma: Executive advisor, Klaus Legau, Corporate Affairs
Email: ugedk@leo-pharma.com

From the Patient Organization: Formand, Anne Vastrup, Atopisk Eksem Forening
Email: anne@vastrup.dk

4 TIME AND PLACE

- 4.1 The Project shall take place in Restaurant Sommer, Havnegade 19, 3770 Allinge from June 13th 2024 at 09.30am to 11.00am

5 FINANCIAL SUPPORT

- 5.1 The financial commitment of LEO Pharma under this Agreement shall be 0DKK (zero DKK) ("Funding"). The amount is exclusive of VAT.

6 INDIRECT- AND NON-FINANCIAL SUPPORT

- 6.1 LEO Pharma will not provide any indirect or non-financial support under this Agreement.

7 TRANSPARENCY AND DISCLOSURE

- 7.1 Information regarding this Agreement may be publicly disclosed on the website of LEO Pharma and its Affiliates in accordance with applicable rules until at least six (6) months after expiry of the Agreement. A copy of the Agreement may until ten (10) years after expiry of the Agreement be made available upon specific request. The Patient Organization acknowledges that LEO Pharma in accordance with applicable rules may be required to notify and disclose to relevant authorities details about the content of this Agreement (e.g. the name of the Patient Organization, a description of the nature Project and value of the support etc.). The Patient Organization consents to such disclosure.

- 7.2 This Agreement shall further be publicly accessible for the same period of time on the Patient Organization's website <https://atopisketsemforening.dk/>.

8 USE OF THE PATIENT ORGANIZATION'S LOGO

- 8.1 The Patient Organization agrees that LEO Pharma may use the Patient Organization's logo or name, and make use of collaboration with the Patient Organization, as follows: on the websites of LEO Pharma, on LEO Pharma's social media channels and in LEO Pharma's online/print media, e.g., the annual report.

9 INDEPENDENCE AND CONFLICT OF INTEREST

- 9.1 The Parties declare by signing this Agreement that the Patient Organization shall be free to collaborate with other pharmaceutical companies and that LEO Pharma shall be free to collaborate with other Patient Organizations. The Parties further state that their collaboration shall not involve exclusive rights with respect to specific product or therapeutic areas or do not include any obligation or inducement to recommend a particular medicinal product.
- 9.2 LEO Pharma agrees by signing this Agreement not to impose conditions for the Patient Organization's professional or stakeholder-policy viewpoints. This Agreement shall not be seen as explicit or implicit agreements that confer an obligation on the Patient Organization to recommend or in any other way promote the interest of LEO Pharma.
- 9.3 LEO Pharma shall not seek to influence any material developed in connection with the Project favourable to its own commercial interest, but may correct factual errors, and may, if requested by the Patient Organization, contribute to the drafting of text from a fair and balanced scientific perspective.

10 TERM AND TERMINATION

10.1 This Agreement shall come into force on the day of the last signature to the Agreement and shall unless terminated earlier, remain in force until the event has taken place on June 13th 2024 after 11.00am, at which date and time the Agreement shall be terminated automatically.

11 DATA PROTECTION

11.1 The Parties undertakes at all times to comply with all applicable laws and regulations applicable to the processing of personal data and data protection.

12 LAW AND VENUE

12.1 This Agreement shall be governed by the laws of Denmark without regard to the conflict of laws provisions.


12.2 Any dispute arising out of or in connection with this Agreement, including any disputes regarding the existence, validity or termination thereof, shall be settled by arbitration administered by the Danish Institute of Arbitration in accordance with the rules of arbitration procedure adopted by the Danish Institute of Arbitration and in force at the time when such proceedings are commenced. The arbitral tribunal shall be composed of three arbitrators. Each Party shall appoint one arbitrator, and the Danish Institute of Arbitration shall appoint the chairman of the arbitration tribunal. If a Party has not appointed an arbitrator within thirty (30) business days of having requested or received notice of the arbitration, such arbitrator shall be appointed by the Danish Institute of Arbitration. The place of arbitration shall be Copenhagen, Denmark and the arbitration shall be conducted in English.

13 SIGNATURES

13.1 The Agreement may be executed in one or more counterparts, each of which shall be an original and all of which shall constitute together the same document. The Parties agree that the execution of this Agreement by standard industry signature software and/or by exchanging PDF signatures shall have the same legal force and effect as the exchange of original signatures. Any amendments of the Agreement shall be in writing and signed by authorized representatives of the Parties.

LEO Pharma A/S

Date: 2. Maj 2024



Name: Klaus Legau

Title: Executive advisor

Atopisk Eksem Forening

Date: 6. maj 2024



Name: Anne Vastrup

Title: Formand

